How can the Rams clinch NFC West division title in Week 17?AP Race Call: Democrat Derek Tran wins election to U.S. House in California's 45th Congressional District, beating incumbent Michelle Steel
The Philadelphia Eagles showed why they are one of the best teams in the league after their dominant win over the Baltimore Ravens on Sunday. The defense held the high-powered Ravens offense to just 19 points, and the offense, led by quarterback Jalen Hurts and running back Saquon Barkley, showed why they are in the MVP conversation. Philadelphia Eagles Waive Receiver The Eagles waived veteran wide receiver Parris Campbell on Monday following their win, meaning he will likely be signed back on to the practice squad after playing in the game against Baltimore. The #Eagles waived veteran WR Parris Campbell. — Tom Pelissero (@TomPelissero) December 2, 2024 Parris Campbell Career Campbell has been in the league since 2019 and has amounted to 1117 receiving yards and six touchdowns in his career. Before playing for the Eagles, the receiver was on the Indianapolis Colts and the New York Giants, but he has not yet shown that he can be a solid starter in the NFL. His best season came in 2022 with the Colts, when he was able to record 63 catches for 623 receiving yards and three touchdowns. Since then, he only has one touchdown that came this season with Philadelphia. Other team fans like the Washington Commanders have been calling for their favorite squad to look into signing Campbell, as he would add good depth to a roster. This article first appeared on Gridiron Heroics and was syndicated with permission.
Luigi Mangione may face an uphill legal battle as a suspect in the shooting of UnitedHealthcare CEO Brian Thompson due to mounting evidence against him.NoneWARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates. “The third quarter of 2024 was marked with significant progress. We were very pleased with the SEISMiC B study results in early cardiogenic shock showing significant improvement in many measures of cardiac function and blood pressure along with a favorable safety profile in patients with heart failure and cardiogenic shock. There have been four positive Phase 2 studies with over 300 patients treated with istaroxime resulting in a consistent, unique and attractive drug profile across a wide range of severities,” said Craig Fraser, Chairman and CEO. “With trial execution and active operations comes the need for capital and we successfully completed transactions providing resources for our near-term needs as well as secured an equity line of credit to potentially support future requirements,” Mr. Fraser added. “Looking forward, we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study with a planned interim data read out in early Q2 2025 as well as providing guidance on our strategy and planned activities with our oncology preclinical aPKCi inhibitor assets. Given what we believe to be strong data and market need, the Company is turning attention to business development activities to secure additional licenses and partnerships for our multi-asset cardiovascular platform with the objective to secure non-dilutive capital and partner resources to advance the assets to potential commercialization.” Key Business Updates Announced positive Phase 2b topline clinical results with istaroxime significantly improving cardiac function and blood pressure in heart failure patients with early cardiogenic shock. The study met its primary endpoint in significantly improving systolic blood pressure over six hours (SBP AUC) for the combined Part A and Part B SEISMiC istaroxime group compared to placebo as well as for SEISMiC Part B alone. The improvements in SBP AUC at 24 hours were also significantly increased by istaroxime and the improvements were sustained through 96 hours of measurement. Cardiac output (the amount of blood pumped by the heart over a minute) and filling pressures in the heart significantly improved as did measured kidney function. Heart failure severity as assessed by the NYHA classification decreased significantly up to 72 hours compared to placebo. A favorable safety and tolerability profile, including risk for cardiac arrythmias, was also observed. The clinical study data was presented in a late-breaker session at the Heart Failure Society of America conference and the Company reviewed the clinical results along with the program strategy and plans at a virtual Investor Meeting which has been posted to the Company website. Completed two private placements in July 2024 for aggregate proceeds of approximately $13.9 million, which consisted of approximately $4.4 million of new funding (with $2.3 million of net proceeds) and a $9.5 million payment through the full cancellation and extinguishment of certain holders outstanding senior notes, including secured notes, and shares of the Company’s Series B Convertible Preferred Stock. Entered into a Common Stock Purchase Agreement with an equity line investor, whereby the Company has the right, but not the obligation, to sell such investor, and, subject to limited exceptions, the investor is obligated to purchase for up to $35 million of newly issued shares of the Company’s common stock. Announced initiation of the SEISMiC C study of istaroxime in SCAI Stage C cardiogenic shock to complete Phase 2b and advance the transition to Phase 3. This is a global trial including sites in the U.S., Europe and Latin America. It is a placebo-controlled, double-blinded study with istaroxime being added to current standard of care with inotropes and/or vasopressors. The effect of istaroxime in addition to these therapies will be assessed for 6 hours and based on the patient’s condition, the ability to remove standard of care therapies while on istaroxime will also be assessed. The primary endpoint of the study is assessment of systolic blood pressure (SBP) profile over the first 6 hours of treatment. Expanded patent estate with new patents with istaroxime in cardiogenic shock and acute heart failure. Cardiogenic shock national phase filings were completed for patent applications around the world, including in the United States, Germany, France, Italy, Japan and China. A patent was issued for istaroxime for Japan entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure and it has been accorded Patent No. 7560134. A patent was issued for istaroxime for Hong Kong, and it is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed formulations comprising istaroxime, pharmaceutically acceptable salts thereof, and methods of use, alone, or in combination with other agents useful for the treatment and management of acute heart failure. Select Third Quarter 2024 Financial Results For the third quarter ended September 30, 2024, the Company reported an operating loss of $4.7 million, which was comparable to an operating loss of $4.7 million in the third quarter of 2023. Included in our operating loss for the third quarter of 2024 is $2.2 million related to the change in fair value of our common stock warrant liability and $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. Research and development expenses were $2.0 million for the third quarter of 2024, compared to $2.1 million for the third quarter of 2023. Research and development expenses for both periods primarily relate to the SEISMiC Extension trial of istaroxime for the treatment of early cardiogenic shock which completed enrollment during the third quarter of 2024. General and administrative expenses for the third quarter of 2024 were $2.8 million, compared to $2.6 million for the third quarter of 2023. For the third quarter of 2024, general and administrative expenses include $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. The Company reported a net loss attributable to common stockholders of $3.8 million ($4.23 per basic share) on 0.9 million weighted-average common shares outstanding for the quarter ended September 30, 2024, compared to a net loss of $4.4 million ($15.47 per basic share) on 0.3 million weighted average common shares outstanding for the comparable period in 2023. As of September 30, 2024, the Company reported cash and cash equivalents of $2.3 million and current liabilities of $14.4 million, which includes an $8.6 million warrant liability. Included in prepaid expenses and other assets as of September 30, 2024 is $0.7 million in receivables related to ELOC Purchase Agreement gross proceeds for sales made during the quarter for which we had not yet received the cash payment. The related net proceeds after the redemption of the Series C Preferred Stock was $0.5 million. In addition, subsequent to September 30, 2024 and through November 22, 2024, we sold an additional 4.3 million shares of Common Stock under the ELOC Purchase Agreement for net proceeds of $2.4 million following mandatory redemption payments on our Series C Preferred Stock. Following these financings, we believe that we have sufficient resources available to fund our business operations through January 2025. Readers are referred to, and encouraged to read in its entirety, the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which was filed with the Securities and Exchange Commission on November 26, 2024, and includes detailed discussions about the Company’s business plans and operations, financial condition, and results of operations. Nasdaq Update On November 21, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC stating that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of it not having timely filed its Quarterly Report on Form 10-Q (“Form 10-Q”) for the quarter ended September 30, 2024 with the Securities and Exchange Commission. Based on the November 26, 2024 filing of the Company’s Form 10-Q and a subsequent letter received from Nasdaq on November 27, 2024 stating the Staff has determined that the Company complies with Nasdaq Listing Rule 5250(c)(1), this matter is now closed. About Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree’s portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: the Company’s ability to secure significant additional capital as and when needed; the Company’s ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company’s other product candidates, including preclinical oncology candidates; the Company’s ability to access the debt or equity markets; the Company’s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company’s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company’s efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates, if approved; the Company’s ability to maintain compliance with the continued listing requirements of Nasdaq; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People’s Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company’s ability to access the capital markets. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information: Eric Curtis ecurtis@windtreetx.com
Ballots, Bloodlines, and Betrayal: Oedipus at the Wyndham
As Nebraska's Democratic Party shrinks, some former party officials call for changeCalifornia lawmakers kicked off a special session of the state Legislature Monday. The reason? To fund a $25 million war chest for anticipated legal battles with incoming President Donald Trump’s administration. As nearly 30 new state lawmakers were sworn into office at the state Capitol in Sacramento, legislative leaders gaveled in a special session called by Gov. Gavin Newsom that’s geared toward protecting undocumented immigrants, reproductive rights, climate policy and more from Trump’s second administration. The regular, two-year legislative session also began Monday, but the special session will allow for a speedier lawmaking process. Newsom has requested the funding for the state Department of Justice and other agencies, which are expected to file a flurry of lawsuits challenging Trump policies — as California Democrats did during the president’s first term. The governor’s ask was introduced in bills Monday by Assemblymember Jesse Gabriel, an Encino Democrat who chairs the body’s budget committee. “We will work with the incoming administration and we want President Trump to succeed in serving all Americans,” Newsom said in a statement. “But when there is overreach, when lives are threatened, when rights and freedoms are targeted, we will take action.” Newsom expects to sign the legislation before Trump is sworn in on Jan. 20, and top Democratic lawmakers are on board. They’ll do the bulk of that work in early January after a break, said Assemblymember Marc Berman, a Menlo Park Democrat. “Just like eight years ago, California must once again do everything we can to protect our 39 million residents and our economy,” he said in an email. “During both the special session and the regular session, we must double down on policies to defend reproductive freedom and autonomy, protect the environment, and invest in science and education.” Republicans, however, blasted the special session as a tone-deaf stunt to raise Newsom’s profile as a Trump foil. Politics observers say the Democratic governor almost surely will run for president in 2028, after his final term ends. “Instead of taking the hint that Californians are growing tired of Democrat incompetence, Newsom is doubling down on his extreme agenda and using his special session to ‘Trump-proof’ California with taxpayer dollars,” California GOP Chairwoman Jessica Millan Patterson said in an email. “It’s clear that Gavin Newsom’s 2028 presidential run is now underway, and Californians are simply pawns in his game.” The $25 million set aside for litigation would be a tiny fraction of California’s $288 billion 2024-25 operating budget. But approving that budget required a series of measures to close a $27.6 billion deficit , including dipping into reserves. It was unclear Monday whether funding legal wars with Trump would come at the expense of other programs. On the campaign trail, Trump slammed California as a den of crime, rampant inflation and homelessness, while taking shots at the Golden State’s top Democrats. He also pledged to use the military to conduct mass deportations of immigrants without proper documentation, fueling anxieties of a “worst-case scenario” among Bay Area immigrant advocates . Democrats including U.S. Senator Alex Padilla, Newsom and Attorney General Rob Bonta say they’ll staunchly defend immigrants and will not cooperate with deportations. Bonta also announced Monday that lawmakers are sponsoring bills to ensure Californians can access medication abortions and empowering the attorney general to seek fines from local governments that restrict abortion providers. “I want to make it unequivocally clear: California will remain a safe haven for reproductive rights and access to abortion care, no matter who is in the White House,” Bonta , a potential candidate to succeed Newsom , said in a statement. After Trump’s victory last month, Newsom and California Democrats quickly laid the groundwork to oppose the incoming Republican administration. It’s a reprise role. During Trump’s first term, California filed 122 lawsuits challenging his administration’s policies under Democratic Attorney General Xavier Becerra. That litigation cost the state $42 million, according to Newsom’s office, and netted some victories. In one case, California and New York successfully sued the U.S. Department of Energy in 2017 to allow energy efficiency standards to go into effect nationally, which were expected to save consumers $8.4 billion and prevent nearly 100 million tons of greenhouse gas emissions. Another victory won California $60 million in federal public safety grants, the governor’s office said. Once again, California’s stand-off with Trump is likely to be a major force in state politics for the next four years. But this time around, Newsom is stressing that he’s open to finding common ground with the former president. Meanwhile, Assembly Speaker Robert Rivas and Senate President Pro Tem Mike McGuire say they’ll be mostly be focusing not on resisting Trump, but making California more affordable, CalMatters reported . In fact, Newsom and Rivas have made overtures to California voters since Republicans nationally swept the November elections, reclaiming the White House and Senate and holding the House of Representatives. He made gains throughout the state in part because of discontent over inflation and living costs. In response, Newsom is touring conservative counties to highlight an economic development plan and has said that Democrats need to focus more on the economy. A spokesperson for Rivas did not return a request for comment by press time. Nearly 30 new lawmakers were also sworn in at the state Capitol on Monday. The new legislature includes a record-breaking number of women — 59 of its 120 members, one seat shy of the same number as men . Democrats still have a complete control on state government, with supermajorities in both chambers of the legislature and holds on all executive seats.
Experts react to Bank of Canada interest rate cutLEADERSHIP Public Service Person of the Year 2024: Alhaji Bashir Adewale Adeniyi (MFR), Comptroller General of Customs
The Chicago White Sox are looking for a "meaningful piece," in return for center fielder Luis Robert Jr., according to The Athletic's Will Sammon, Katie Woo and Ken Rosenthal . Potential trade partners seem to be seeking "something for nothing," according to the White Sox, with one executive stating, "I don't think they understand what his value is," per Sammon, Woo, and Rosenthal. The White Sox aren't demanding multiple prospects for Robert Jr. but feel that teams are overreaching in trade negotiations for the 27-year-old. According to one rival executive, the White Sox are also "rightly asking high" in trade discussions involving left-handed pitcher Garrett Crochet, per Sammon, Woo, and Rosenthal. It was reported on Nov. 25 that the White Sox would "love to unload" Robert Jr. before they trade away Crochet, according to USA Today's Bob Nightengale . The team signed Robert Jr. to a six-year, $50 million contract five years ago, expecting big things from the outfielder. However, the 27-year-old has struggled to meet those expectations. "The guy is certainly intriguing, but they've got a really high price tag on him," one anonymous general manager said, per Nightengale. "You've got to hope he finally stays healthy and can be the player everyone envisioned all along. But the White Sox are acting like he's some big star center fielder and are asking for your top prospects." Robert Jr. has spent all five of his professional seasons with the White Sox, recording 88 career home runs, 245 RBI and a .267 batting average. He also boasts a 2023 Silver Slugger Award and a 2020 Gold Glove Award. The White Sox finished last season with a 41-121 record, ranking last in both the American League Central Division and the entire AL. Robert Jr. finished the season with 14 home runs, 35 RBI and a .224 batting average while leading the team with 141 strikeouts in 100 games.FARGO — An annual retreat is teaching students compassion, respect and a sense of community right here in Fargo. On Friday, Nov. 22, Jefferson Elementary fifth graders participated in their school's 2024 Day of Compassion retreat. It was led by some Fargo North High school students, along with inspirational speaker and lay pastor at First Lutheran Church, Rollie Johnson. The retreat featured games, skits, presentations and small group discussions. They addressed issues on bullying and exclusion. Then found ways to use their words and actions to help those who may feel alone. One of the fifth graders said it helped him understand compassion. "Make sure nobody's left alone, and always invite people to play with you, and always make sure people are never left alone in stuff," Jerardo Gonzalez, a student at Jefferson Elementary school, says. The day ended with a Sacred Circle and candlelight campfire.Teddi wrote on Instagram: "The only person who can change your life is you. We have two options: pretend to be a victim or stand up and fight for yourself. We all deserve peace and happiness. I have cried and mourned. I have taken accountability and apologized for things I have done wrong. Now, I have given myself permission to grow and thrive. "There are three sides to every story. How can I stand up and show up for the people that do matter? This is called being an adult. This is what saying it with my full chest means. (sic)" Teddi filed for a divorce earlier this month, describing it via social media as a "difficult decision". The reality star felt that being "open, honest and vulnerable was the best path forward" for her. In a statement posted on Instagram, Teddi - who has Slate, 12, Cruz, ten, and Dove, four, with Edwin - wrote: "After a great deal of care and consideration, I have made the difficult decision to file for divorce. My priority is my children and ensuring that every care is taken with their privacy and wellbeing throughout this new chapter. "Making a public statement is not something I wanted to do but in an effort to protect my family from undue speculation and rumors, I felt being open, honest and vulnerable was the best path forward. (sic)"
iClick Interactive Asia Group Limited Reports 2024 Half-Year Unaudited Financial ResultsChito Miranda nidepensa sa asawa, Neri Naig, human kini madakpi